The Initial Report of Local Control on RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Treated Without Surgery

Best Practice in Advanced Esophageal Cancer: A Report on TransTasman Radiation Oncology Group TROG 03.01 and NCIC CTG ES.2 Multinational Phase 3 Study in Advanced Esophageal Cancer (OC) ComparingQualityofLife(QOL)andPalliationofDysphagia inPatients TreatedWith Radiation Therapy (RT) or Chemoradiation Therapy (CRT) M.G. Penniment, J.A. Harvey, R. Wong, S. Stephens, H. Au, C.J. O’Callaghan, A.B. Kneebone, S. Ngan, I.G. Ward, R. Roy, T. Sullivan, T. Nijjar, J. Biagi, and L.A. Mulroy; Royal Adelaide Hospital, Adelaide, Australia, Princess Alexandra Hospital, Wooloongabba, Australia, Princess Margaret Hospital, Toronto, ON, Canada, Cross Cancer Institute, Edmonton, AB, Canada, National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada, Royal North Shore Hospital, St Leonards, Australia, Peter MacCallum Cancer Centre, East Melbourne, Australia, Canterbury Regional Cancer and Hematology Service Christchurch Hospital, Christchurch, New Zealand, Castle Hill Hospital, Queen’s Centre for Oncology and Hematology, Hull, United Kingdom, University of Adelaide, Adelaide, Australia, Department of Radiation Oncology, Cross Cancer Institute, Edmonton, AB, Canada, Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON, Canada, QEII Health Sciences Centre, Halifax, NS, Canada